Loading...
01/11 11:27
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Despite strong revenue growth and a new partnership with Novo Nordisk, the earnings miss, high operating expenses, and vague management responses in the Q&A session create uncertainty. The lack of clear guidance on reimbursement and revenue split, alongside cash flow concerns, offset the positive impact of the partnership and product launches. The neutral shareholder return plan further contributes to a neutral sentiment.
YORVIPATH Revenue €44.7 million, up from €13.6 million in Q4 2024, driven by strong U.S. launch and steady growth outside the U.S.
SKYTROFA Revenue €51.3 million, stable pricing and market share, but impacted by seasonal factors including reduced channel inventory and higher copay assistance.
Total Revenue €101 million, includes non-product revenue from collaboration partners.
R&D Costs €86.6 million, up from €70.7 million in Q1 2024, previous year included a favorable €10.6 million reversal of prior period write downs.
SG&A Expenses €101 million, up from €66.8 million in Q1 2024, primarily due to global commercial expansion.
Total Operating Expenses €188 million for Q1 2025.
Non-Cash Gain from Visen IPO €33.6 million recognized as part of share of profit loss of associates.
Net Finance Expenses €15.9 million, driven primarily by non-cash items.
Net Cash Financial Income €3.3 million.
Cash and Cash Equivalents €518 million, down from €560 million as of December 31, 2024.
YORVIPATH Launch: YORVIPATH was prescribed in the U.S. by more than 1,000 unique prescribers for over 1,750 patients, with Q1 global revenue growing to €45 million.
SKYTROFA Revenue: Q1 revenues for SKYTROFA were €51 million, with a 7% market share in the total growth hormone market in the U.S.
TransCon CNP Development: TransCon CNP is set to become a key product in the growth disorder strategy, with an NDA submitted to the FDA in March and an MAA expected in Q3.
YORVIPATH Market Positioning: YORVIPATH is the first FDA approved treatment for hypoparathyroidism in adults, addressing a significant unmet medical need.
SKYTROFA Market Positioning: SKYTROFA is established as a high-value brand with potential for label expansion beyond its current indication.
Revenue Growth: Total revenue for Q1 was €101 million, with significant contributions from YORVIPATH and SKYTROFA.
Cash Position: Cash and cash equivalents totaled €518 million at the end of Q1 2025.
Regulatory Strategy: Plans to submit an IND for TransCon CNP in combination with TransCon Growth Hormone for hypoparathyroidism treatment.
Vision 2030: Collaboration with Novo Nordisk and others to create value in various therapeutic areas.
Earnings Miss: Ascendis Pharma reported an EPS of $-1.79348, missing expectations of $-1.56, indicating potential financial instability.
Regulatory Risks: The company is navigating ongoing regulatory processes for its product candidates, which could impact timelines and market entry.
Market Competition: Ascendis faces competitive pressures in the biopharma sector, particularly in the growth hormone market, where they hold a 7% market share.
Supply Chain Challenges: There are potential supply chain challenges that could affect the availability and distribution of their products, particularly with the global launch of YORVIPATH.
Economic Factors: Fluctuations in the Euro-dollar exchange rate may impact reported revenue, adding an economic risk factor.
R&D Expenses: R&D costs increased to €86.6 million, indicating a significant investment that may not yield immediate returns.
SG&A Expenses: SG&A expenses rose to €101 million, driven by global commercial expansion, which could strain financial resources.
Cash Flow Concerns: Despite a cash balance of €518 million, ongoing high expenses raise concerns about future cash flow sustainability.
YORVIPATH Launch: Ascendis Pharma reported a strong U.S. launch of YORVIPATH, with over 1,000 unique prescribers and more than 1,750 patients prescribed as of March 31, 2025. The company expects YORVIPATH to significantly contribute to revenue in 2025.
SKYTROFA Positioning: SKYTROFA is established as a high-value brand in the growth hormone market, with plans for label expansion and a basket trial for various indications.
TransCon CNP Development: TransCon CNP is in development for achondroplasia, with an NDA submitted to the FDA in March 2025 and an MAA expected in Q3 2025.
Combination Therapy Trials: Ascendis is conducting the COACH Trial, the first Phase 2 study combining TransCon CNP and growth hormone for achondroplasia.
Vision 2030: Ascendis aims to create value in various therapeutic areas through innovative business models and collaborations.
Revenue Expectations: Ascendis expects substantial revenue growth in 2025 driven by YORVIPATH and continued contributions from SKYTROFA.
Financial Projections: Total revenue for Q1 2025 was €101 million, with expectations for continued growth in both YORVIPATH and SKYTROFA.
Cash Position: As of Q1 2025, Ascendis had cash and cash equivalents totaling €518 million.
Operating Expenses: Total operating expenses for Q1 2025 were €188 million, with R&D costs at €86.6 million and SG&A expenses at €101 million.
Shareholder Return Plan: Ascendis Pharma has not announced any share buyback program or dividend program during the Q1 2025 earnings call.
The earnings call presents a strong financial performance with expected revenue growth from YORVIPATH and SKYTROFA, supported by label expansions and global launches. The company anticipates becoming cash flow positive, which is a positive indicator. The Q&A section highlights confidence in overcoming challenges, with high patient retention rates and strategic market penetration. The overall sentiment is positive, supported by optimistic guidance and strategic growth plans, likely leading to a stock price increase in the short term.
The earnings call reveals a strong financial performance with significant revenue growth and a successful launch of YORVIPATH. Despite increased SG&A expenses due to global expansion, the company shows a positive outlook with steady patient enrollment and high compliance rates. The Q&A section highlighted management's efforts to improve processes and their optimistic view of market potential. Although some guidance was not provided, the overall sentiment is positive, suggesting a potential stock price increase of 2% to 8% over the next two weeks.
Despite strong revenue growth and a new partnership with Novo Nordisk, the earnings miss, high operating expenses, and vague management responses in the Q&A session create uncertainty. The lack of clear guidance on reimbursement and revenue split, alongside cash flow concerns, offset the positive impact of the partnership and product launches. The neutral shareholder return plan further contributes to a neutral sentiment.
The earnings call presents a mixed sentiment. Positive aspects include strong revenue growth for YorvaPath and collaboration with Novo Nordisk. However, there are concerns about rising operating expenses and supply chain challenges. The Q&A reveals uncertainties in reimbursement and lack of clarity in some responses, leading to a cautious market sentiment. No shareholder return plan was announced, which might disappoint investors. The overall sentiment is neutral, with no major negative or positive catalysts to significantly impact the stock price.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
